Evidence map›Paper›PMID 29039461›Full record

ArticleInternational journal of oncology2017

Effects of ursolic and oleanolic on SK‑MEL‑2 melanoma cells: In vitro and in vivo assays.

Angela Caunii, Camelia Oprean, Mirabela Cristea, Alexandra Ivan, Corina Danciu, Calin Tatu, Virgil Paunescu, Daniela Marti, George Tzanakakis, Demetrios A Spandidos and 5 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Antiproliferative Activity ofPharmaceuticals (Basel, Switzerland) · 2022
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Angela CauniiFaculty of Pharmacy, 'Victor Babeş' University of Medicine and Pharmacy, 300041 Timişoara, Romania.
Camelia OpreanFaculty of Pharmacy, 'Victor Babeş' University of Medicine and Pharmacy, 300041 Timişoara, Romania.
Mirabela Cristea'Pius Brinzeu' Timișoara County Emergency Clinical Hospital, Oncogen Institute, 300723 Timişoara, Romania.
Alexandra Ivan'Pius Brinzeu' Timișoara County Emergency Clinical Hospital, Oncogen Institute, 300723 Timişoara, Romania.
Corina DanciuFaculty of Pharmacy, 'Victor Babeş' University of Medicine and Pharmacy, 300041 Timişoara, Romania.
Calin Tatu'Pius Brinzeu' Timișoara County Emergency Clinical Hospital, Oncogen Institute, 300723 Timişoara, Romania.
Virgil Paunescu'Pius Brinzeu' Timișoara County Emergency Clinical Hospital, Oncogen Institute, 300723 Timişoara, Romania.
Daniela MartiFaculty of Medicine, Western University Vasile Goldis, Arad 310025, Romania.
George TzanakakisFaculty of Medicine, University of Crete, 71003 Heraklion, Crete, Greece.
Demetrios A SpandidosFaculty of Medicine, University of Crete, 71003 Heraklion, Crete, Greece.
Aristides TsatsakisFaculty of Medicine, 'Victor Babeş' University of Medicine and Pharmacy, 300041 Timişoara, Romania.
Razvan SusanFaculty of Medicine, 'Victor Babeş' University of Medicine and Pharmacy, 300041 Timişoara, Romania.
Codruta SoicaFaculty of Pharmacy, 'Victor Babeş' University of Medicine and Pharmacy, 300041 Timişoara, Romania.
Stefana AvramFaculty of Pharmacy, 'Victor Babeş' University of Medicine and Pharmacy, 300041 Timişoara, Romania.
Cristina DeheleanFaculty of Pharmacy, 'Victor Babeş' University of Medicine and Pharmacy, 300041 Timişoara, Romania.
Victor Babeș University of Medicine and Pharmacy Timișoara · ROSpitalul Clinic Judeţean de Urgenţă "Pius Brînzeu" Timişoara · ROUniversity of Crete · GRVasile Goldis Western University of Arad · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among the triterpenoids, oleanolic acid (OA) and its isomer, ursolic acid (UA) are promising therapeutic candidates, with potential benefits in the management of melanoma. In this study, we aimed to examine the in vitro and in vivo anti‑invasive and anti‑metastatic activity of OA and UA to determine their possible usefulness as chemopreventive or chemotherapeutic agents in melanoma. For the in vitro experiments, the anti‑proliferative activity of the triterpenic compounds on SK‑MEL‑2 melanoma cells was examined. The anti‑invasive potential was assessed by testing the effects of the active compound on vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM) adhesion to melanoma cells. Normal and tumor angiogenesis were evaluated in vivo by chicken embryo chorioallantoic membrane (CAM) assay. The two test triterpenoid acids, UA and OA, exerted differential effects in vitro and in vivo on the SK‑MEL‑2 melanoma cells. UA exerted a significant and dose‑dependent anti‑proliferative effect in vitro, compared to OA. The cytotoxic effects in vitro on the melanoma cells were determined by the examining alterations in the cell cycle phases induced by UA that lead to cell arrest in the S phase. Moreover, UA was found to affect SK‑MEL‑2 melanoma cell invasiveness by limiting the cell adhesion capacity to ICAM molecules, but not influencing their adhesion to VCAM molecules. On the whole, in this study, by assessing the effects of the two triterpenoids in vivo, our results revealed that OA had a greater potential to impair the invasive capacity and tumor angiogenesis compared with UA.

Indexed as

Angiogenesis InhibitorsAnimalsCell AdhesionCell CycleCell Line, TumorCell ProliferationChick EmbryoChorioallantoic MembraneHumansMelanomaNeovascularization, PhysiologicOleanolic AcidSkin NeoplasmsTriterpenesUrsolic AcidAngiogenesis InhibitorsOleanolic AcidTriterpenesUrsolic Acid

Identifiers

PMID29039461
PMCPMC5673023
OpenAlexW2766441270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.